Sign In
Last checked at 
2 Jun 2021 07:00
2 June 2021
PureTech Health plc
PDMR Notifications
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announces that awards of restricted share units ("RSUs") granted by PureTech on 15 June 2018 to certain directors and other persons discharging managerial responsibilities ("PDMRs") pursuant to its Performance Share Plan ("PSP") vested in full on 15 February 2021 following satisfaction of all of the performance conditions measured over the three year period to 31 December 2020.
Bharatt Chowrira received vested ordinary shares (after deduction of shares for payroll taxes). The Company's Remuneration Committee exercised its discretion in accordance with the Company's remuneration policy and the rules of the PSP and cash settled the vested ordinary shares of Daphne Zohar, Joseph Bolen, and Eric Elenko in full, resulting in those PDMRs receiving cash (after deduction of payroll taxes) instead of ordinary shares in the Company.
The market price per ordinary share in the Company used to calculate the amount payable to the PDMRs and the amount of shares to be issued to PDMRs was 387 pence, being the average closing price of the Company's shares over the three trading day period immediately preceding the settlement, and the exchange rate used to calculate the cash payment and amount of share settlement was £1:$1.417133.
The Company's total issued ordinary share capital is 286,431,217 shares after the share issuance to Bharatt Chowrira and other share issuances to non PDMR employees.
PDMR Notification
The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||||
a) | Name | Bharatt Chowrira
| ||||||||
2 | Reason for the notification | |||||||||
a) | Position/status | Bharatt Chowrira - President and Chief of Business and Strategy | ||||||||
b) | Initial notification/Amendment | Initial Notification | ||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | PureTech Health plc | ||||||||
b) | LEI | 213800LVPDNO2Z9T9I39 | ||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the financial instrument, type of instrument |
| ||||||||
b) | Nature of the transaction | Issuance of ordinary shares in net settlement of certain vested RSUs under the PureTech Health Performance Share Plan, after retentions in respect of payroll taxes. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
|
| ||||||||
e) | Date of the transaction | 1 June 2021 | ||||||||
f) | Place of the transaction | London Stock Exchange (XLON) | ||||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||||
a) | Name | Daphne Zohar Joseph Bolen Eric Elenko
| ||||||||
2 | Reason for the notification | |||||||||
a) | Position/status | Daphne Zohar - Chief Executive Officer Joseph Bolen - Chief Scientific Officer Eric Elenko - Chief Innovation Officer
| ||||||||
b) | Initial notification/Amendment | Initial Notification | ||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | PureTech Health plc | ||||||||
b) | LEI | 213800LVPDNO2Z9T9I39 | ||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the financial instrument, type of instrument |
| ||||||||
b) | Nature of the transaction | Payment by PureTech Health plc in net settlement of a cash amount equivalent to the value of Ordinary Shares on the vesting of certain RSUs under the PureTech Health Performance Share Plan, in each case after retentions in respect of payroll taxes | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
|
| ||||||||
e) | Date of the transaction | 1 June 2021 | ||||||||
f) | Place of the transaction | Outside a trading venue | ||||||||
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 26 therapeutics and therapeutic candidates, including two that have received FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report on Form 20-F. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Contact: Investors |
Allison Mead Talbot +1 617 651 3156 amt@puretechhealth.com |
Follow the stocks
